(Q54562078)

1 June 2018

title

Implications of rarity of chromosome 17 polysomy in breast cancer. (English)

1 reference

1 June 2018

author

Cathy B Moelans

series ordinal

1

1 reference

1 June 2018

Jorge Reis-Filho

series ordinal

2

object named as

Jorge S Reis-Filho

1 reference

1 June 2018

Paul J van Diest

3

1 reference

1 June 2018

publication date

6 September 2011

1 reference

1 June 2018

Lancet Oncology Commission

published in

1 reference

1 June 2018

volume

12

1 reference

1 June 2018

page(s)

1087-1089

1 reference

1 June 2018

issue

12

1 reference

1 June 2018

The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970234-0

7 January 2021

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970234-0

7 January 2021

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970234-0

7 January 2021

Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970234-0

7 January 2021

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970234-0

7 January 2021

Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970234-0

7 January 2021

Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970234-0

7 January 2021

HER2 status and benefit from adjuvant trastuzumab in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970234-0

7 January 2021

10.1016/S1470-2045(11)70234-0

Identifiers

DOI

1 reference

1 June 2018

PubMed ID

21903472

1 reference

1 June 2018